SCHEMBL4670907

SCHEMBL4670907

O=C(C=C(O)c1nc[nH]n1)c1cc(Cc2ccccc2F)co1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 1/20 0.35
PTPN1 P18031 1/20 0.34
HDAC6 Q9UBN7 1/20 0.33
AR P10275 1/20 0.33
HCAR3 P49019 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
NTRK1 P04629 1/20 0.32
PTGER4 P35408 1/20 0.32
NR3C2 P08235 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
SNCA P37840 2/20 0.31
GPR84 Q9NQS5 1/20 0.31
KDM4E B2RXH2 1/20 0.31
RAB9A P51151 1/20 0.31
KDM5A P29375 1/20 0.31
KDM5B Q9UGL1 1/20 0.31
AKR1C3 P42330 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676464 0.88 BRS3 (0.35) BRS3ARPTGER4SNCAGPR84
SCHEMBL4674095 0.87 AR (0.36) ARNTRK1NR3C2SNCAKDM4E
SCHEMBL4679147 0.87 PTGER4 (0.35) PTGER4KDM5AKDM5B
SCHEMBL4671631 0.86 BRS3 (0.38) BRS3ARMEN1KMT2ANR3C2
SCHEMBL4673435 0.84 LMNA (0.36) BRS3KMT2AKDM4E
SCHEMBL4675734 0.84 HCAR2 (0.40) BRS3MEN1KMT2ANR3C2SNCA
SCHEMBL4670701 0.84 CES1 (0.35) BRS3PTPN1HDAC6ARHCAR3
SCHEMBL4674108 0.83 AR (0.32) PTPN1HDAC6ARHCAR3MEN1
SCHEMBL4677006 0.82 POLB (0.34) MEN1KMT2APTGER4KDM4ERAB9A
SCHEMBL4677051 0.82 TAAR1 (0.37) BRS3MEN1KMT2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 BRS3 3289/4885PTPN1 2715/4885HDAC6 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.